Welcome to Francis Academic Press

Frontiers in Medical Science Research, 2022, 4(3); doi: 10.25236/FMSR.2022.040310.

Meta-analysis of the Expression Level and Significance of miR-21 in Cancer Tissues of Patients with Prostate Cancer


Haiyang Li

Corresponding Author:
Haiyang Li

Department of Urology, Gansu Provincial Hospital, Lanzhou730000, China


Prostate cancer is the second leading cause of cancer-related death in men. MicroRNAs are thought to have a potential role in tumorigenesis. In this paper, the significance of the expression level of mir-21 in prostate cancer patients and its Meta-analysis were investigated. For this study, MiR-21 and prostate cancer detection methods were first described in detail, and then a model was established for the detection of prostate cancer, and the image was divided into foreground and background parts according to the selected threshold, and the prostate image was detected. The data of prostate cancer patients were collected, divided into four types: well-differentiated cancer, moderately differentiated cancer, poorly differentiated cancer and undifferentiated cancer, and then they were stained to analyse the changes in the expression level of miR-21 in the experimental subjects. The experiments showed that when circulating miR-21 levels were elevated, potential patients were 4.3 times more likely to develop cancer than healthy controls.


Prostate Cancer; Cancer Tissue Cells; Mir-21; Expression Levels and Meta Analysis

Cite This Paper

Haiyang Li. Meta-analysis of the Expression Level and Significance of miR-21 in Cancer Tissues of Patients with Prostate Cancer. Frontiers in Medical Science Research (2022) Vol. 4, Issue 3: 52-56. https://doi.org/10.25236/FMSR.2022.040310.


[1] Kim M Y , Shin H , Moon H W , et al. Urinary exosomal microRNA profiling in intermediate-risk prostate cancer[J]. Scientific Reports, 2021, 11(1):7355.

[2] Logozzi M, Angelini D F, Iessi E, et al. Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients[J]. Cancer letters, 2017, 403(3): 318-329.

[3] Stuopelyt K, K Daniūnait? Jankevi?Ius F , et al. Detection of miRNAs in urine of prostate cancer patients[J]. Medicina, 2017, 52(2):116-124.

[4] Jairath N K, Dal Pra A, Vince Jr R, et al. A systematic review of the evidence for the decipher genomic classifier in prostate cancer [J]. European urology, 2021, 79(3): 374-383.

[5] Seraphin T P, Joko‐Fru W Y, Hämmerl L, et al. Presentation, patterns of care, and outcomes of patients with prostate cancer in sub-Saharan Africa: a population‐based registry study [J]. Cancer, 2021, 127(22): 4221-4232.

[6] Davis I D, Martin A J, Stockler M R, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer[J]. New England Journal of Medicine, 2019, 381(2): 121-131.

[7] Redman J M, Gulley J L, Madan R A. Combining immunotherapies for the treatment of prostate cancer[C]//Urologic Oncology: Seminars and Original Investigations. Elsevier, 2017, 35(12): 694-700.

[8] Gao M. Application analysis of PLC technology in automatic control of ship auxiliary machinery [J]. Journal of Coastal Research, 2020, 115(51): 130-132.

[9] Hofman M S, Lawrentschuk N, Francis R J, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study [J]. The Lancet, 2020, 395(10231): 1208-1216.

[10] Liu Y, Cheng S, Ning B, et al. Robust model predictive control with simplified repetitive control for electrical machine drives [J]. IEEE Transactions on Power Electronics, 2018, 34(5): 4524-4535.